Travere Therapeutics Inc Ordinary Shares TVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TVTX is a good fit for your portfolio.
News
-
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
-
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
-
Calliditas Therapeutics stock jumps as kidney treatment gets FDA approval
-
Travere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatments
-
Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial
-
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say
-
Travere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug
-
Travere Therapeutics Shares Touch 52-Week Low on FSGS Study Data
Trading Information
- Previous Close Price
- $5.75
- Day Range
- $5.40–5.76
- 52-Week Range
- $5.26–22.74
- Bid/Ask
- $5.48 / $5.49
- Market Cap
- $417.84 Mil
- Volume/Avg
- 459,605 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 380
- Website
- https://www.travere.com
Comparables
Valuation
|
Metric
|
TVTX
|
CBAY
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.20 | 12.65 | 1.59 |
Price/Sales | 2.99 | 111.01 | 468.26 |
Price/Cash Flow | — | — | — |
Price/Earnings
TVTX
CBAY
PLRX
Financial Strength
|
Metric
|
TVTX
|
CBAY
|
PLRX
|
|---|---|---|---|
Quick Ratio | 3.31 | 10.70 | 17.43 |
Current Ratio | 3.47 | 10.96 | 17.72 |
Interest Coverage | −34.10 | −5.27 | −145.34 |
Quick Ratio
TVTX
CBAY
PLRX
Profitability
|
Metric
|
TVTX
|
CBAY
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −2.68% | −30.06% | −22.68% |
Return on Equity (Normalized) | −12.41% | −51.97% | −24.50% |
Return on Invested Capital (Normalized) | −5.04% | −30.87% | −28.46% |
Return on Assets
TVTX
CBAY
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ndssvtbtx | Mhbd | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wkxzvpxp | Tkzgbn | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ydrkrsjkx | Lphjyf | $99.6 Bil | |
MRNA
| Moderna Inc | Mdwywwbwd | Kqhz | $38.8 Bil | |
ARGX
| argenx SE ADR | Vtxjkqp | Cqnz | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Fmtflll | Kfxvn | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qwcjbwzrn | Swhgz | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Szbqzrdr | Tmzdg | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jmmtzdxmjq | Wpwpy | $12.4 Bil | |
INCY
| Incyte Corp | Hcgrqhb | Xkpxv | $11.9 Bil |